Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CER Has Been A Part Of CMS Coverage Decisions In Recent Years – Avalere

This article was originally published in The Gray Sheet

Executive Summary

During the health care reform debate, much concern was expressed that results of comparative effectiveness research from the Patient-Centered Outcomes Research Institute could play a key role in Medicare coverage decisions.

You may also be interested in...



CMS Changes Gears On MRI Coverage In Pacemaker Patients

Under an April 25 proposal, pacemaker patients not enrolled in a clinical trial would be eligible for Medicare-reimbursed magnetic resonance imaging scans, under certain conditions, if their implant is FDA-approved for use in the MRI environment.

MRI For Pacer Patients: Coverage Limited To Studies

CMS has finalized a proposal from last year to cover magnetic resonance imaging scans of patients with pacemaker and defibrillator implants, but only in certain well-controlled studies, while maintaining its MRI coverage restriction for patients with the implants in all other contexts.

"Dynamic Pricing" Would Use CER To Save Medicare Costs

Despite barriers built into the health reform law to prevent use of comparative cost analyses to set Medicare reimbursement rates, allowing such analyses could enable billions in savings, according to an article in the October issue of Health Affairs

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel